Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA 2018 | CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML

Simon Cheesman • 12 Oct 2018
BOPA 2018

From the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Simon Cheesman, MRPharmS, from University College London, London, UK, describes the key outcomes from the Phase III trial (NCT01696084) looking at CPX-351, a liposomal formulation of daunorubicin and cytarabine (DA), in a patient group aged between 60-75 years old. Compared with conventional DA chemotherapy, CPX-351 showed superior efficacy in terms of overall survival, with a comparable toxicity profile. Mr Cheeseman emphasizes the fact that dose administration is simpler and more convenient for both HCPs and patients.

More from Simon Cheesman

0:54
The switch to biosimilar rituximab at UCH: 12 months on
Simon Cheesman • 12 Oct 2018
1:16
Practical intricacies surrounding biosimilar adoption
Simon Cheesman • 6 Oct 2017
1:12
An audit of infusion-related reactions with biosimilar rituximab in London
Simon Cheesman • 6 Oct 2017
The introduction of biosimilar rituximab: a case study from the pharmacist's perspective
Simon Cheesman • 7 Oct 2017
The content of VJHemOnc is intended for healthcare professionals